Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9712661 | 0.87 | GABRA1 (0.48) | CYP1A2CYP2C19ALDH1A1LMNAKDM4E | |
| Ethane SCHEMBL2154466 | 0.85 | GABRA1 (0.46) | CYP1A2CYP2C19ALDH1A1LMNAKDM4E | |
| SCHEMBL16956630 | 0.84 | CYP1A2 (0.44) | CYP1A2CYP2C19ALDH1A1LMNAKDM4E | |
| SCHEMBL15534580 | 0.82 | S1PR1 (0.48) | CYP1A2CYP2C19ALDH1A1LMNAKDM4E | |
| SCHEMBL12490229 | 0.82 | CYP1A2 (0.46) | CYP1A2CYP2C19ALDH1A1LMNAKDM4E | |
| SCHEMBL23754863 | 0.82 | CYP1A2 (0.46) | CYP1A2CYP2C19ALDH1A1LMNAKDM4E | |
| SCHEMBL11359423 | 0.82 | CYP1A2 (0.46) | CYP1A2CYP2C19ALDH1A1LMNAKDM4E | |
| SCHEMBL13179961 | 0.82 | CYP1A2 (0.46) | CYP1A2CYP2C19ALDH1A1LMNAKDM4E | |
| SCHEMBL8930901 | 0.81 | CYP1A2 (0.42) | CYP1A2CYP2C19ALDH1A1LMNAKDM4E | |
| SCHEMBL1535598 | 0.81 | GABRA1 (0.45) | CYP1A2ALDH1A1SMN1; SMN2GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037453-B2 | Aromatic polyethers containing a biosourced furan diol | ROQUETTE FRERES (FR) | 2024-07-16 | — | — | US | disclosed |
| EP-3841147-B1 | AROMATIC POLYETHERS CONTAINING A BIOSOURCED FURAN DIOL | ROQUETTE FRERES (FR) | 2023-10-04 | — | — | EP | disclosed |
| EP-3444238-B1 | PROCESS FOR PREPARING DIFLUOROMETHYLENE COMPOUNDS | SATO PHARMA (JP) | 2021-12-08 | — | — | EP | disclosed |
| US-20210317265-A1 | AROMATIC POLYETHERS CONTAINING A BIOSOURCED FURAN DIOL | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-10-14 | — | — | US | disclosed |
| EP-3444238-A2 | PROCESS FOR PREPARING DIFLUOROMETHYLENE COMPOUNDS | Sato Pharmaceutical Co., Ltd. (JP) | 2019-02-20 | — | — | EP | disclosed |
| US-9650380-B2 | Difluoromethylene compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2017-05-16 | — | — | US | disclosed |
| US-9650380-B2 | Difluoromethylene compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2017-05-16 | — | — | US | disclosed |
| US-20170044158-A1 | DIFLUOROMETHYLENE COMPOUND | SATO PHARMACEUTICAL CO., LTD. (JP) | 2017-02-16 | — | — | US | disclosed |
| US-20170044158-A1 | DIFLUOROMETHYLENE COMPOUND | SATO PHARMACEUTICAL CO., LTD. (JP) | 2017-02-16 | — | — | US | disclosed |
| US-9512119-B2 | Difluoromethylene compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2016-12-06 | — | — | US | disclosed |
| EP-1610779-B1 | 3-OXO-1,3-DIHYDRO-INDAZOLE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AS PHOSPHOLIPASE INHIBITORS | LILLY CO ELI (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20060276522-A1 | Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors | ELI LILLY AND COMPANY (US) | 2006-12-07 | — | — | US | disclosed |
| US-20060211755-A1 | 3-oxo-1, 3-dihydro-indazole-2-carboxylic acid amide derivatives as phospholipase inhibitors | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2006-09-21 | — | — | US | disclosed |
| US-20060148796-A1 | 6-Substituted imidazopyrazines | ALTANA PHARMA AG (DE) | 2006-07-06 | — | — | US | disclosed |
| EP-1615900-A1 | BENZISOTHIAZOL-3-ONE-CARBOXYLIC ACID AMIDES AS PHOSPHOLIPASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-01-18 | — | — | EP | disclosed |
| EP-1610779-A1 | 3-OXO-1,3-DIHYDRO-INDAZOLE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AS PHOSPHOLIPASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-01-04 | — | — | EP | disclosed |
| EP-1599481-A1 | 6-SUBSTITUTED IMIDAZOPYRAZINES | ALTANA Pharma AG (DE) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004093872-A1 | 3-OXO-1, 3-DIHYDRO-INDAZOLE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AS PHOSPHOLIPASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004094394-A1 | BENZISOTHIAZOL-3-ONE-CARBOXYLIC ACID AMIDES AS PHOSPHOLIPASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004074289-A1 | 6-SUBSTITUTED IMIDAZOPYRAZINES | ALTANA PHARMA AG (DE) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044158-A1 | DIFLUOROMETHYLENE COMPOUND | XDH, URB2, MNAT1 | CYP1A2 663/4885CYP2C19 1786/4885ALDH1A1 271/4885 |
| US-20060211755-A1 | 3-oxo-1, 3-dihydro-indazole-2-carboxylic acid amide derivatives as phospholipase inhibitors | C5AR2, C3AR1, C5AR1 | CYP1A2 1343/4885CYP2C19 1493/4885ALDH1A1 2776/4885 |
| US-20060276522-A1 | Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors | LIPG, PNLIP, LIPC | CYP1A2 2235/4885CYP2C19 2706/4885ALDH1A1 464/4885 |
| US-20060148796-A1 | 6-Substituted imidazopyrazines | VIP, GIPR, SI | CYP1A2 77/4885CYP2C19 185/4885ALDH1A1 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.